Analyse

Analyses approfondies des marchés pharmaceutiques, des chaînes d'approvisionnement, de la technologie et de la réglementation

#Celltrion ×

22 sept. 2026•1 min de lecture

Celltrion's OmliClon Biosimilar Gains Strong Market Share in Europe

Celltrion's omalizumab biosimilar OmliClon expands to 26 European countries, achieving over 90% market share in Spain and exceeding sales targets in Italy.

7 sept. 2026•1 min de lecture

Celltrion's Ramcima SC and US Zimpenra post 4.56 trillion KRW H1 sales

Ramcima SC and Zimpenra together generated 4.562 trillion KRW in the first half of the year, with strong growth in Europe and the US.

6 sept. 2026•1 min de lecture

Celltrion expands Omliclo omalizumab biosimilar line with 300 mg launch in Europe

Celltrion has introduced the 300 mg dose of its omalizumab biosimilar Omliclo in Germany, the UK and France, extending its European portfolio for chronic urticaria and allergic asthma.

3 sept. 2026•1 min de lecture

Celltrion Accelerates Biosimilar Growth in Europe and US, Launches CT-P68 Trial

Celltrion’s biosimilar business is building a virtuous growth cycle, expanding sales in Europe and the US while initiating a Phase 1 trial of CT-P68, a tremfya biosimilar.

31 août 2026•1 min de lecture

Celltrion Biosimilars Gain Momentum in Europe, Omliclo Reaches 16% Share Q1

Celltrion's follow‑on biosimilars are expanding in Europe, with Omliclo achieving about 16% market share in Q1 2024, driven by a first‑mover strategy and direct sales network.

30 août 2026•1 min de lecture

Celltrion’s bevacizumab biosimilar ‘베그젤마’ added to major US PBM formularies

Celltrion’s biosimilar 베그젤마 (bevacizumab) has been listed in Express Scripts and Optum formularies, strengthening its US oncology market foothold.

30 août 2026•1 min de lecture

Celltrion Beats Q2 Market Expectations, Analysts Raise Target Prices

Celltrion reported Q2 revenue of 1.3 trillion KRW and operating profit of 430 billion KRW, surpassing consensus estimates, prompting analysts to lift target prices.